(Q35819025)

English

Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study.

scientific article published on 12 October 2011

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21994233%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study (English)

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21994233%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

0 references

1 reference

based on heuristic

inferred from title

psoriatic arthritis

1 reference

based on heuristic

inferred from title

RESPOND investigators

10

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21994233%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

3

object named as

N V Kungurov

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21994233%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

author name string

Asta Baranauskaite

1

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21994233%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Helena Raffayová

2

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21994233%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Anna Kubanova

4

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21994233%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Algirdas Venalis

5

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21994233%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Laszlo Helmle

6

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21994233%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Shankar Srinivasan

7

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21994233%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Evgeny Nasonov

8

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21994233%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Nathan Vastesaeger

9

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21994233%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

language of work or name

0 references

publication date

12 October 2011

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21994233%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Annals of the Rheumatic Diseases

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21994233%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

71

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21994233%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

4

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21994233%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

541-548

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21994233%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Psoriatic arthritis from Wright's era until today

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3298666

27 July 2018

Treatment recommendations for psoriatic arthritis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3298666

27 July 2018

Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3298666

27 July 2018

Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3298666

27 July 2018

Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3298666

27 July 2018

Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3298666

27 July 2018

European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3298666

27 July 2018

Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3298666

27 July 2018

Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3298666

27 July 2018

Clinical indicators of progression in psoriatic arthritis: multivariate relative risk model

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3298666

27 July 2018

Longitudinal study of clinical and radiological progression in psoriatic arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3298666

27 July 2018

European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3298666

24 September 2018

Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3298666

24 September 2018

Psoriatic arthritis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3298666

24 September 2018

Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3298666

24 September 2018

Mortality in psoriatic arthritis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3298666

24 September 2018

The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3298666

24 September 2018

Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3298666

24 September 2018

Inflammatory joint manifestations are prevalent in psoriasis: prevalence study of joint and axial involvement in psoriatic patients, and evaluation of a psoriatic and arthritic questionnaire

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3298666

15 November 2018

Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT)

1 reference

https://pubmed.ncbi.nlm.nih.gov/21994233

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

METHOTREXATE THERAPY IN PSORIATIC ARTHRITIS; DOUBLE-BLIND STUDY ON 21 PATIENTS

1 reference

https://pubmed.ncbi.nlm.nih.gov/21994233

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/21994233

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A comparative evaluation of quality of life and life satisfaction in patients with psoriatic and rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/21994233

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982-1991

1 reference

https://pubmed.ncbi.nlm.nih.gov/21994233

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression

1 reference

https://pubmed.ncbi.nlm.nih.gov/21994233

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized, double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/21994233

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1136/ARD.2011.152223

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21994233%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21994233%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21994233%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35819025&oldid=2136400285"